Liqiang  Xi, M.D.
Liqiang Xi, M.D.
Staff Scientist

Center for Cancer Research
National Cancer Institute

Building 10, Room 2N110
Bethesda, MD 20892
301-594-1525

Dr. Xi worked with a translational clinical research team for 8 years at the University of Pittsburgh School of Medicine and later at the Mount Sinai School of Medicine, New York. This research was focused on identification of molecular markers to reliably detect cancer metastasis to lymph nodes or blood, and on molecular signatures of cancer by employing the cutting-edge technologies at the time, such as TaqMan real-time quantitative RT-PCR, gene expression microarrays, microRNA expression profiling, and genome wide whole exon microarrays.

At the NCI, Dr. Xi serves as the technical director for the Molecular Diagnostics Laboratory, Laboratory of Pathology, supervising a broad array of CLIA-certified molecular diagnostics activities from traditional fragment analysis for detection of B cell and T cell clonality in lymphoma and RT-PCR assays for fusion gene detection in sarcoma, to cancer gene mutation testing using the most cutting-edge technology, next generation sequencing.

Areas of Expertise
lymphoma, sarcoma, gene mutation

Dr. Xi worked with a translational clinical research team for 8 years at the University of Pittsburgh School of Medicine and later at the Mount Sinai School of Medicine, New York. This research was focused on identification of molecular markers to reliably detect cancer metastasis to lymph nodes or blood, and on molecular signatures of cancer by employing the cutting-edge technologies at the time, such as TaqMan real-time quantitative RT-PCR, gene expression microarrays, microRNA expression profiling, and genome wide whole exon microarrays.

At the NCI, Dr. Xi serves as the technical director for the Molecular Diagnostics Laboratory, Laboratory of Pathology, supervising a broad array of CLIA-certified molecular diagnostics activities from traditional fragment analysis for detection of B cell and T cell clonality in lymphoma and RT-PCR assays for fusion gene detection in sarcoma, to cancer gene mutation testing using the most cutting-edge technology, next generation sequencing.

In addition to research and development of new molecular tests that support molecular diagnostics and personalized cancer therapies, Dr. Xi's research interests currently focus on analysis of circulating tumor DNA in melanoma to measure the immunotherapy response, and targeted mutational analysis of uncommon types of lymphoma.

Selected Publications
  1. Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.
    Blood. 119: 3330-2, 2012. [ Journal Article ]
  2. Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, Dennis PA, Giaccone G, Raffeld M.
    Clin Lung Cancer. 14: 452-6, 2013. [ Journal Article ]
  3. Xi L, Luketich JD, Raja S, Gooding WE, Litle VR, Coello MC, Finkelstein SD, Chestney ML, Landreneau RJ, Hughes SJ, Godfrey TE.
    Clin. Cancer Res.. 11: 1099-109, 2005. [ Journal Article ]
  4. Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE.
    Clin. Chem.. 53: 1206-15, 2007. [ Journal Article ]
  5. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ, Litle VR, Pennathur A, Luketich JD, Godfrey TE.
    Nucleic Acids Res.. 36: 6535-47, 2008. [ Journal Article ]

Dr. Xi completed his medical education in China. He obtained his M.S. in toxicology and occupational health from the Chinese Center for Disease Control and Prevention. He pursued postdoctoral training at the UC Berkeley School of Public Health and the University of Pittsburgh Graduate School of Public Health, where he studied biomarkers of environmental carcinogenesis. While in Pittsburgh he also studied and obtained his M.S. in information science with a focus in bioinformatics. Prior to joining the NCI Laboratory of Pathology, Dr. Xi was a research assistant professor at the Department of Pathology, Mount Sinai School of Medicine, New York. He has co-authored 2 patents and over 60 scientific publications.

Summary

Dr. Xi worked with a translational clinical research team for 8 years at the University of Pittsburgh School of Medicine and later at the Mount Sinai School of Medicine, New York. This research was focused on identification of molecular markers to reliably detect cancer metastasis to lymph nodes or blood, and on molecular signatures of cancer by employing the cutting-edge technologies at the time, such as TaqMan real-time quantitative RT-PCR, gene expression microarrays, microRNA expression profiling, and genome wide whole exon microarrays.

At the NCI, Dr. Xi serves as the technical director for the Molecular Diagnostics Laboratory, Laboratory of Pathology, supervising a broad array of CLIA-certified molecular diagnostics activities from traditional fragment analysis for detection of B cell and T cell clonality in lymphoma and RT-PCR assays for fusion gene detection in sarcoma, to cancer gene mutation testing using the most cutting-edge technology, next generation sequencing.

Areas of Expertise
lymphoma, sarcoma, gene mutation

Research

Dr. Xi worked with a translational clinical research team for 8 years at the University of Pittsburgh School of Medicine and later at the Mount Sinai School of Medicine, New York. This research was focused on identification of molecular markers to reliably detect cancer metastasis to lymph nodes or blood, and on molecular signatures of cancer by employing the cutting-edge technologies at the time, such as TaqMan real-time quantitative RT-PCR, gene expression microarrays, microRNA expression profiling, and genome wide whole exon microarrays.

At the NCI, Dr. Xi serves as the technical director for the Molecular Diagnostics Laboratory, Laboratory of Pathology, supervising a broad array of CLIA-certified molecular diagnostics activities from traditional fragment analysis for detection of B cell and T cell clonality in lymphoma and RT-PCR assays for fusion gene detection in sarcoma, to cancer gene mutation testing using the most cutting-edge technology, next generation sequencing.

In addition to research and development of new molecular tests that support molecular diagnostics and personalized cancer therapies, Dr. Xi's research interests currently focus on analysis of circulating tumor DNA in melanoma to measure the immunotherapy response, and targeted mutational analysis of uncommon types of lymphoma.

Publications

Selected Publications
  1. Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.
    Blood. 119: 3330-2, 2012. [ Journal Article ]
  2. Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, Dennis PA, Giaccone G, Raffeld M.
    Clin Lung Cancer. 14: 452-6, 2013. [ Journal Article ]
  3. Xi L, Luketich JD, Raja S, Gooding WE, Litle VR, Coello MC, Finkelstein SD, Chestney ML, Landreneau RJ, Hughes SJ, Godfrey TE.
    Clin. Cancer Res.. 11: 1099-109, 2005. [ Journal Article ]
  4. Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE.
    Clin. Chem.. 53: 1206-15, 2007. [ Journal Article ]
  5. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ, Litle VR, Pennathur A, Luketich JD, Godfrey TE.
    Nucleic Acids Res.. 36: 6535-47, 2008. [ Journal Article ]

Biography

Dr. Xi completed his medical education in China. He obtained his M.S. in toxicology and occupational health from the Chinese Center for Disease Control and Prevention. He pursued postdoctoral training at the UC Berkeley School of Public Health and the University of Pittsburgh Graduate School of Public Health, where he studied biomarkers of environmental carcinogenesis. While in Pittsburgh he also studied and obtained his M.S. in information science with a focus in bioinformatics. Prior to joining the NCI Laboratory of Pathology, Dr. Xi was a research assistant professor at the Department of Pathology, Mount Sinai School of Medicine, New York. He has co-authored 2 patents and over 60 scientific publications.